Monopar Therapeutics Inc. — Q1 2019 Form 10-Q
Reporting period: Three months ended March 31, 2019; balance-sheet comparisons are against December 31, 2018. Monopar is a clinical-stage oncology biopharmaceutical company with no approved products and no product revenue.
Key financial metrics
| Metric | Q1 2019 / March 31, 2019 | Comparable period / prior balance date |
|---|---|---|
| Revenue | $0 | $0 in Q1 2018 |
| Research and development | $835,600 | $457,141 in Q1 2018 |
| General and administrative | $571,709 | $440,119 in Q1 2018 |
| Total operating expenses | $1,407,309 | $897,260 in Q1 2018 |
| Net loss | $1,376,235; $0.15 per share | $876,347; $0.09 per share in Q1 2018 |
| Operating cash used | $995,972 | $808,849 in Q1 2018 |
| Cash and cash equivalents | $5,881,064 | $6,892,772 at December 31, 2018 |
| Current assets / current liabilities | $6,353,804 / $579,986 | $7,317,955 / $399,551 at December 31, 2018 |
| Total liabilities | $579,986 | No debt reported; liabilities were primarily current payables, accruals, and lease liability |
Gross and operating margins are not meaningful because the company reported no revenue. Net loss widened by about $500,000 year over year. Cash declined by about $1.01 million during the quarter. Financing cash outflow was $13,855, principally deferred offering costs; there was no investing cash flow.
Business context and material changes
- Pipeline: Validive (clonidine MBT), described as Phase 3-ready for severe oral mucositis associated with oropharyngeal cancer; camsirubicin, a Phase 2-stage doxorubicin analog; and MNPR-101, a pre-IND antibody targeting uPAR.
- R&D expense rose approximately $378,000, primarily from CRO and related preparation fees and clinical-material manufacturing for Validive, partly offset by lower regulatory consulting costs.
- G&A expense rose approximately $132,000, mainly due to stock-based compensation, salaries, and board fees, partly offset by lower patent legal costs.
- Stock-based compensation expense was $233,776 versus $114,526 in Q1 2018. No options were granted in Q1 2019.
Outlook, risks, and contingencies
- Management planned to initiate Validive’s Phase 3 program in the second half of 2019, following FDA feedback on the protocol and statistical analysis plan. The proposed program includes an adaptive trial with an interim analysis and a planned confirmatory trial.
- The company planned a larger randomized Phase 2 camsirubicin trial and anticipated seeking an FDA pre-IND meeting for MNPR-101 after identifying a clinical-material manufacturer.
- Management estimated available resources would fund minimum required operations through June 2020 and, based on its April 2019 assessment, reported no substantial doubt about going concern. It also expects increasing expenses and says additional capital will be needed for development; funding plans include equity, debt, collaborations, and grants. The runway estimate is subject to assumptions and execution risks.
- Validive’s Onxeo license carries potential development, regulatory, and sales milestones of up to $108 million and royalties of 5%–10% on net sales. MNPR-101’s XOMA license has potential milestones of up to $14.925 million and no sales royalties. No milestones were reached or payments triggered in Q1.
- No material legal proceedings were reported. The company disclosed no off-balance-sheet arrangements. Cash balances at one bank exceeded the FDIC-insured limit.
- Effective January 1, 2019, the company adopted the lease accounting standard and recorded a $22,676 right-of-use asset and lease liability. It reported no material changes to risk factors from its 2018 Form 10-K.
Important facts for investors to verify
- Whether Validive’s Phase 3 start, trial design, timing, and funding needs progressed as planned after the filing date.
- Whether the estimated cash runway through June 2020 remains achievable given planned development spending and the need for additional financing.
- The filing’s December 31, 2018 accumulated-deficit figures are inconsistent: the balance sheet reports $21,655,412, while the stockholders’ equity statement reports $21,655,712.
- The cover reports 9,291,420.614 shares outstanding as of May 10, 2019, while the financial statements report 9,291,421 shares; verify the precise share count and potential dilution from 1,105,896 outstanding options.